Skudexa: Uses, Dosage & Side Effects

What Is Skudexa and What Is It Used For?

Skudexa belongs to a pharmacological class known as fixed-dose combination analgesics. Each film-coated tablet contains two active substances with different mechanisms of action that together target pain through both central and peripheral pathways. The opioid component, tramadol hydrochloride, is a centrally acting analgesic that works on the brain and spinal cord, while the NSAID component, dexketoprofen trometamol, acts primarily at the site of tissue injury to reduce inflammation and peripheral pain signals. This multimodal approach — sometimes referred to as "balanced analgesia" — has become a cornerstone of acute pain management in modern clinical practice because it often delivers better pain relief at lower doses of each individual component than single-agent therapy.

Tramadol is a synthetic opioid analgesic that exerts its effects through two mechanisms. First, it binds weakly to mu-opioid receptors in the central nervous system, producing opioid-mediated analgesia. Second, it inhibits the reuptake of serotonin and norepinephrine at nerve synapses, enhancing descending inhibitory pain pathways that dampen incoming pain signals. The active metabolite O-desmethyltramadol (M1), produced by the liver enzyme CYP2D6, has substantially greater affinity for the mu-opioid receptor than the parent compound and contributes significantly to analgesia. Because CYP2D6 activity varies widely between individuals, clinical response to tramadol can differ considerably from one person to another.

Dexketoprofen is the pharmacologically active S(+)-enantiomer of ketoprofen, a traditional NSAID. By isolating the active enantiomer, dexketoprofen achieves equivalent or superior analgesic effect at roughly half the dose of racemic ketoprofen, potentially improving the gastrointestinal and cardiovascular tolerability profile. Dexketoprofen acts by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the enzymes responsible for converting arachidonic acid into prostaglandins. Prostaglandins are key mediators of inflammation, pain, and fever, so blocking their synthesis reduces swelling, tenderness, and pain at injured or inflamed tissues. Dexketoprofen also has a relatively rapid onset of analgesic action compared with several other NSAIDs, which makes it particularly useful in acute pain settings.

Skudexa is officially indicated for the short-term symptomatic treatment of moderate to severe acute pain in adults when a combination of tramadol and an NSAID is considered appropriate. Typical clinical situations in which the combination may be prescribed include moderate to severe post-operative pain following orthopedic, abdominal, or gynecological surgery; acute musculoskeletal pain such as lower back pain, neck pain, and acute sprains or strains; acute pain following trauma; and moderate to severe dental pain including pain after third-molar (wisdom tooth) extraction. Use in chronic pain, inflammatory rheumatic disease (for example, rheumatoid arthritis or osteoarthritis), and cancer pain is not recommended; more appropriate regimens exist for those conditions.

Clinical trials that supported the approval of the tramadol 75 mg / dexketoprofen 25 mg combination demonstrated significantly greater pain relief compared with either component alone at equivalent single-agent doses. Multiple randomized controlled studies in acute post-operative pain, dental pain, and acute musculoskeletal pain models showed that the combination provided faster onset, stronger peak analgesia, and longer duration of pain relief than monotherapy, while allowing each component to be used at moderate doses. This synergism is the scientific rationale that justifies a fixed-dose combination rather than taking tramadol and dexketoprofen as separate tablets.

What Should You Know Before Taking Skudexa?

Contraindications

Skudexa combines two pharmacologically active substances and therefore carries contraindications specific to each component, as well as combined contraindications. Because both tramadol and dexketoprofen can cause serious adverse effects in certain populations, the list of absolute contraindications is broader than for single-agent analgesics. Understanding these contraindications is essential before treatment begins.

Skudexa must not be used in the following situations:

• Known allergy to tramadol, dexketoprofen, aspirin, ibuprofen, naproxen, or any other NSAID, or to any of the inactive ingredients. Allergic reactions can range from mild skin rashes to severe anaphylaxis.
• A history of asthma, bronchospasm, nasal polyps, urticaria, angioedema, or other hypersensitivity reactions triggered by aspirin or other NSAIDs.
• Active peptic ulcer disease, active gastrointestinal bleeding, or a history of NSAID-associated gastrointestinal bleeding or perforation. Two or more episodes of confirmed ulcer disease or GI bleeding are also a contraindication.
• Chronic inflammatory bowel disease such as Crohn's disease or ulcerative colitis during an active flare.
• Severe heart failure (NYHA class IV), ischemic heart disease, peripheral arterial disease, or a recent history of stroke or transient ischemic attack.
• Severe liver impairment (Child-Pugh score 10–15) or active hepatic disease.
• Severe renal impairment (creatinine clearance below 30 mL/min) or clinically significant kidney disease.
• Known hemorrhagic diathesis or coagulation disorders that increase the risk of bleeding.
• Uncontrolled epilepsy. Tramadol lowers the seizure threshold and can trigger convulsions in susceptible individuals.
• Acute intoxication with alcohol, sleeping pills, opioids, or psychotropic drugs that affect consciousness.
• Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or use of MAOIs in the previous 14 days. This combination can cause life-threatening serotonin syndrome.
• The third trimester of pregnancy and during breastfeeding.
• Children and adolescents under 18 years of age.
• Severe dehydration including dehydration caused by vomiting, diarrhea, or inadequate fluid intake, due to the risk of acute kidney injury from the NSAID component.

Warnings and Precautions

Before starting Skudexa, it is critical to inform your healthcare provider about your complete medical history. Several conditions require special attention, dose adjustments, or close monitoring while you are on treatment:

• History of gastrointestinal disease: Patients with previous peptic ulcer, GI bleeding, dyspepsia, or Helicobacter pylori infection are at increased risk of recurrent bleeding. Co-administration of a proton pump inhibitor may be appropriate in high-risk patients. The risk is greatest in older adults.
• Cardiovascular disease: NSAIDs, including dexketoprofen, have been associated with an increased risk of myocardial infarction, stroke, and worsening heart failure, particularly with higher doses and longer durations of use. Use the shortest possible treatment duration in patients with uncontrolled hypertension, congestive heart failure (NYHA class II–III), established cardiovascular disease, or risk factors such as diabetes, smoking, and hyperlipidemia.
• Kidney disease and dehydration: NSAIDs can cause a dose-dependent reduction in prostaglandin-mediated renal blood flow and may precipitate acute kidney injury, especially in patients who are elderly, volume depleted, or taking diuretics, ACE inhibitors, or angiotensin II receptor blockers. Ensure adequate hydration throughout treatment.
• Liver disease: Both tramadol and dexketoprofen are metabolized by the liver. Patients with mild to moderate hepatic impairment require dose adjustment, close monitoring, and should avoid prolonged use.
• Asthma: About 10% of asthmatic patients have aspirin-sensitive asthma, in which NSAIDs can trigger acute bronchospasm. Skudexa should be used with great caution in asthmatics and avoided in those with known NSAID sensitivity.
• History of substance abuse or psychiatric illness: The tramadol component can cause physical and psychological dependence. Patients with a personal or family history of opioid, alcohol, or other substance abuse, or with depression or anxiety, are at higher risk.
• Epilepsy or risk factors for seizures: Tramadol lowers the seizure threshold, especially at higher doses or when combined with SSRIs, SNRIs, tricyclic antidepressants, antipsychotics, or other drugs that also lower the seizure threshold.
• Head injury or raised intracranial pressure: The opioid component can mask clinical signs of neurological deterioration and may increase intracranial pressure.
• Respiratory disease: Tramadol can cause dose-dependent respiratory depression, particularly in patients with chronic obstructive pulmonary disease, obstructive sleep apnea, neuromuscular disease, or when combined with other CNS depressants.
• Adrenal insufficiency: Long-term or repeated opioid exposure can cause secondary adrenal insufficiency with symptoms of chronic fatigue, weight loss, hypotension, and hypoglycemia.

Masking of infection: Like other NSAIDs, dexketoprofen can mask the typical signs of infection, including fever, by reducing prostaglandin-mediated inflammation. This means an infection could progress further before it is recognized. If you feel worse while taking Skudexa, develop new symptoms, or have an unexplained rise in body temperature, contact your doctor.

CYP2D6 metabolizer status: Tramadol is converted into its more active metabolite (M1) by the CYP2D6 enzyme. Ultra-rapid metabolizers (approximately 1–10% of the population depending on ethnicity) convert tramadol to M1 very quickly and may experience unexpectedly strong opioid effects, including severe drowsiness, confusion, very small pupils, slow breathing, and respiratory depression, even at standard doses. Poor metabolizers (approximately 5–10% of Caucasians) produce very little M1 and may experience inadequate pain relief.

Pregnancy and Breastfeeding

Skudexa is contraindicated during the third trimester of pregnancy and during breastfeeding. During the first and second trimesters, Skudexa should not be used unless clearly necessary. Both active ingredients can harm the developing fetus through different mechanisms, and safer alternatives are available for pain relief in pregnancy.

The dexketoprofen component can cause fetal kidney dysfunction, oligohydramnios, and premature closure of the ductus arteriosus if used during the third trimester, leading to pulmonary hypertension in the newborn. It can also prolong labor and increase the risk of maternal and neonatal bleeding. In the first and second trimesters, regular or prolonged NSAID use has been associated with an increased risk of miscarriage and congenital malformations.

The tramadol component crosses the placenta and can cause neonatal respiratory depression and neonatal opioid withdrawal syndrome with symptoms such as irritability, tremors, poor feeding, and high-pitched crying. Both tramadol and dexketoprofen are excreted in breast milk, and Skudexa should not be used while breastfeeding.

Women planning pregnancy should be aware that NSAIDs may temporarily reduce fertility by interfering with ovulation. This effect is reversible after stopping the medication but is an important consideration for women who are actively trying to conceive.

Children and Adolescents

The safety and efficacy of Skudexa have not been established in people under 18 years of age, and it is not recommended in this population. Use of tramadol in children and adolescents carries particular concerns about respiratory depression, especially in ultra-rapid CYP2D6 metabolizers, and regulatory agencies including the FDA and EMA have issued specific warnings against using tramadol-containing products in children under 12 and in adolescents with obesity, obstructive sleep apnea, or severe lung disease.

Elderly Patients

Elderly patients (aged 65 years and above) are at higher risk of both gastrointestinal bleeding from the NSAID component and CNS adverse effects including drowsiness, confusion, and falls from the opioid component. Renal and hepatic function often decline with age, which can reduce clearance of both tramadol and dexketoprofen. Skudexa should be used with great caution in the elderly, at the lowest effective dose, for the shortest possible duration, and only after careful consideration of alternative pain-management strategies.

Driving and Operating Machinery

Skudexa commonly causes drowsiness, dizziness, visual disturbances, and impaired concentration. Do not drive, operate heavy machinery, or perform other tasks that require full alertness until you know how the medication affects you. The risk of impairment is greater at the start of treatment, after dose changes, and when Skudexa is taken with alcohol or other CNS depressants.

How Does Skudexa Interact with Other Drugs?

Because Skudexa contains two active substances, the interaction profile is the combined profile of tramadol and dexketoprofen. The opioid component primarily drives interactions with CNS depressants, serotonergic drugs, and seizure-threshold-lowering agents, while the NSAID component drives interactions with drugs affecting the gastrointestinal tract, bleeding risk, renal function, and blood pressure regulation. The following tables summarize the most clinically important interactions.

Major Interactions

Moderate Interactions

This is not a complete list of all possible interactions. Tell your doctor and pharmacist about every medicine you take, including over-the-counter products (such as ibuprofen or aspirin), herbal products (such as St John's Wort, which can precipitate serotonin syndrome), vitamins, and recreational substances. Clinical pharmacists play a critical role in screening for interactions before Skudexa is dispensed.

What Is the Correct Dosage of Skudexa?

Dose individualization is a cornerstone of safe analgesic prescribing. For Skudexa, however, the fixed-dose format means that adjustments are made by changing the interval between tablets or the total number of tablets per day, rather than by altering the ratio between tramadol and dexketoprofen. The prescribing principle is to use the lowest effective dose for the shortest possible duration. Before starting treatment, your doctor should discuss realistic expectations for pain control, how long you should take Skudexa, how to taper or stop treatment, and which symptoms should prompt you to seek medical advice.

Adults

Elderly Patients (≥ 65 years)

Patients with Kidney Impairment

Patients with Liver Impairment

Children and Adolescents

Missed Dose

If you forget to take a dose, take it as soon as you remember unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two tablets at once to make up for a forgotten dose, as doubling the dose significantly increases the risk of adverse effects, including respiratory depression, gastrointestinal bleeding, and acute kidney injury.

Overdose

What Are the Side Effects of Skudexa?

Like all medicines, Skudexa can cause side effects, although not everyone experiences them. Because the tablet contains two active substances, the side-effect profile combines the adverse-effect profiles of tramadol (opioid-type effects) and dexketoprofen (NSAID-type effects). Most reactions are mild to moderate and tend to improve as the body adjusts to treatment, but some are serious and require immediate medical attention. The frequency grid below summarizes adverse effects reported in clinical trials and post-marketing surveillance.

Withdrawal symptoms: Although Skudexa is intended for short-term use, repeated courses or high-dose exposure to the tramadol component can still lead to physical and psychological dependence. If treatment is stopped abruptly after more than a few consecutive days of use, you may experience opioid-type withdrawal symptoms including restlessness, anxiety, sweating, tremor, insomnia, sneezing, yawning, nausea, diarrhea, and muscle aches. In rare cases more severe symptoms (panic attacks, hallucinations, paranoia, unusual sensory experiences) have been described. If you have been taking Skudexa for more than the recommended 5 days, discuss gradual dose reduction with your doctor rather than stopping abruptly.

Reporting side effects: If you experience a side effect that is not listed here or that worsens, tell your doctor or pharmacist. Reporting side effects helps strengthen ongoing pharmacovigilance and improves safety information for future patients. Most countries offer national medicines safety reporting schemes that accept reports directly from patients or caregivers.

How Should You Store Skudexa?

Skudexa should be kept in its original carton and blister pack to protect the tablets from light and moisture. No special refrigeration is required. The medication should be stored at or below 30 °C (86 °F). Avoid storing it in warm or humid environments such as bathrooms, which can accelerate degradation of both active ingredients.

Because Skudexa contains tramadol, a controlled substance in many jurisdictions, it must be stored securely, out of the sight and reach of children, teenagers, and anyone else for whom it has not been prescribed. Accidental ingestion — particularly by young children — can be fatal because of rapid-onset respiratory depression. A locked cabinet or secured medicine box is strongly recommended. Never share Skudexa with another person, even if their symptoms appear similar to yours.

Always check the expiry date on the carton and blister strip before each use. The expiry date refers to the last day of the indicated month. Do not use tablets that appear discolored, chipped, crumbling, or otherwise altered in appearance. Do not dispose of Skudexa via household waste or by flushing it down the toilet, as medicinal products can contaminate the environment. Return any unused or expired tablets to your local pharmacy, which has established procedures for safe, environmentally responsible disposal of prescription medications.

What Does Skudexa Contain?

Each film-coated Skudexa tablet contains the following active substances:

• Tramadol hydrochloride 75 mg — a centrally acting synthetic opioid analgesic with dual mechanisms of action (weak mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake).
• Dexketoprofen trometamol 25 mg — equivalent to 17 mg of dexketoprofen free acid. Dexketoprofen is the pharmacologically active S(+)-enantiomer of racemic ketoprofen and inhibits both COX-1 and COX-2 to reduce prostaglandin-mediated inflammation and pain.

Typical inactive ingredients (excipients) used in the tablet core include microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, colloidal anhydrous silica, and magnesium stearate. The film coating usually contains hypromellose, titanium dioxide (E171), macrogol (polyethylene glycol), talc, and may include iron oxide coloring agents (E172) to give the tablet its characteristic appearance. The precise excipient list may vary between countries and production batches; always consult the patient information leaflet accompanying your pack for the definitive list relevant to your specific product.

Skudexa does not contain lactose, gluten, or sucrose in its standard formulation, making it suitable for patients with these specific intolerances. However, patients with known allergies to any excipient or to chemically related compounds (for example, other iron-oxide colorants) should review the leaflet carefully. If you are uncertain whether you can take Skudexa safely, ask your pharmacist, who can cross-reference the full ingredient list against your allergy history.

Skudexa is supplied as film-coated tablets in blister packs of 4, 10, 20, or 30 tablets. Not all pack sizes may be marketed in every country. The marketing authorization holder is Menarini International Operations Luxembourg SA, and local distribution is carried out by national subsidiaries of the Menarini Group in each country where the product is licensed.